These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2558622)

  • 61. Effects of cicletanine on prostaglandin I2 and E2 levels in patients with essential hypertension.
    Yasu T; Imanishi M
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):750-5. PubMed ID: 9234829
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of the effect of cicletanine on genetic atherosclerosis in the rabbit.
    Hudson P; Holland TK; McCraw AP; Duffen J; Sim AK
    Arch Mal Coeur Vaiss; 1989 Nov; 82 Spec No 4():71-7. PubMed ID: 2514673
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effect of acute and subchronic treatment with cicletanine on DOCA-salt hypertension in the rat.
    Fuentes JA; Castro A; Alsasua A
    Am J Hypertens; 1989 Sep; 2(9):718-20. PubMed ID: 2803677
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Evaluation of the efficacy and safety of monotherapy for significant essential hypertension in adolescents with use of enalapril].
    Cichocka E; Wyszyńska T; Januszewicz P; Kawalec W
    Pediatr Pol; 1995 Feb; 70(2):145-51. PubMed ID: 7603798
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Renal effect of anti-hypertensive drugs depends on sodium diet in the excision remnant kidney model.
    Terzi F; Beaufils H; Laouari D; Burtin M; Kleinknecht C
    Kidney Int; 1992 Aug; 42(2):354-63. PubMed ID: 1405318
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension.
    Assadi F
    J Nephrol; 2014 Feb; 27(1):51-6. PubMed ID: 24519863
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of cicletanine on renal cGMP production.
    Valdivielso JM; Morales AI; Pérez-Barriocanal F; López-Novoa JM
    Can J Physiol Pharmacol; 1998 Dec; 76(12):1151-5. PubMed ID: 10326838
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cicletanine and hypertensive retinopathy.
    Ruchoux MM; Droy-Lefaix MT; Bakri F; Guillemain J; Ruchoux P; Autret A
    Ophthalmic Res; 1990; 22(5):318-29. PubMed ID: 2090985
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of sodium restriction and enalapril in persons with moderate to severe hypertension.
    Anderson A; Morgan TO; Wilson D; Nowson C; Murphy J; Snowden R
    Med J Aust; 1987 Feb; 146(3):149-53. PubMed ID: 3033455
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Pharmacologic control of hypertension in the population of the right-bank Warsaw districts based on research from the Pol-Monica study].
    Rywik S; Kuźmińska A; Wagrowska H; Kurjata P
    Wiad Lek; 1990 Jan 1-15; 43(1-2):39-46. PubMed ID: 2368384
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effect of cicletanine on cerebrovascular injury in stroke-prone spontaneously hypertensive rats.
    Ruchoux MM; Huguet F; Droy-Lefaix MT; Gelot A; Ruchoux P; Autret A
    Am J Hypertens; 1989 Sep; 2(9):683-9. PubMed ID: 2803675
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term effects of cicletanine on secondary pulmonary hypertension.
    Saadjian A; Philip-Joët F; Paganelli F; Arnaud A; Levy S
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):364-71. PubMed ID: 9514180
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Evaluation of the efficacy and the tolerance of cicletanine in hypertensive subjects over 65 years of age. Three frequent clinical situations in urban practice].
    Amah G; Westerloppe J
    Presse Med; 1995 Dec 16-23; 24(39):1912-6. PubMed ID: 8745548
    [No Abstract]   [Full Text] [Related]  

  • 74. [Prognostic significance of factors of membrane pathology in hypertension].
    Babadzhan VD
    Lik Sprava; 2003; (1):40-2. PubMed ID: 12712607
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Enalapril/nitrendipine. ENEAS, nitrendipine/enalapril.
    Drugs R D; 2002; 3(2):119-20. PubMed ID: 12001814
    [No Abstract]   [Full Text] [Related]  

  • 76. Cicletanine: new insights into its pharmacological actions.
    Kalinowski L; Szczepańska-Konkel M; Jankowski M; Angielski S
    Gen Pharmacol; 1999 Jul; 33(1):7-16. PubMed ID: 10428010
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Some aspects of the effectiveness of the pathogenetic treatment of schoolchildren with the initial stages of primary arterial hypertension].
    Sarana VA; Gaĭdaĭ VIa; Novikova VN; Terebkova IV
    Pediatr Akus Ginekol; 1976; ():16-8. PubMed ID: 951091
    [No Abstract]   [Full Text] [Related]  

  • 78. Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.
    Todd PA; Goa KL
    Drugs; 1992 Mar; 43(3):346-81. PubMed ID: 1374319
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Evaluation of the effectiveness of a cicletanine-enalapril combination in hypertensive patients].
    Safar M; Cournot P; Duchier J
    Arch Mal Coeur Vaiss; 1989 Nov; 82 Spec No 4():119-24. PubMed ID: 2558622
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Cicletanine administered with other antihypertensive agents].
    Grimberg D; Tarrade T; Deschamps de Paillette E
    Arch Mal Coeur Vaiss; 1989 Nov; 82 Spec No 4():109-12. PubMed ID: 2575368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.